Sagimet Biosciences (SGMT) Cash & Equivalents (2022 - 2026)

Sagimet Biosciences' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $36.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 43.41% year-over-year to $36.6 million; the TTM figure through Mar 2026 stood at $36.6 million (down 43.41% YoY), while the FY2025 annual figure was $35.0 million, down 53.82% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $36.6 million, up from $35.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $176.8 million in Q1 2024, with the low at $158000.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $64.7 million (2025), against an average of $64.0 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 47456.33% in 2023, then plunged 63.39% in 2025.
• Sagimet Biosciences' Cash & Equivalents stood at $158000.0 in 2022, then surged by 47456.33% to $75.1 million in 2023, then climbed by 0.93% to $75.8 million in 2024, then tumbled by 53.82% to $35.0 million in 2025, then gained by 4.58% to $36.6 million in 2026.
• Business Quant data shows SGMT's Cash & Equivalents at $36.6 million in Q1 2026, $35.0 million in Q4 2025, and $32.5 million in Q3 2025.